Programme

November 9, 2019

INTRODUCTION
Introduction to the meeting • A.L. Catapano
EAS activities and initiatives • L. Tokgözoglu


PREVENTION: WHEN SHOULD WE START?
Early intervention for future benefit • Matteo Pirro


NON PHARMACOLOGICAL THERAPEUTIC APPROACHES
Lifestyle interventions • Carlos Escobar
Role of nutraceuticals • Maciej Banach
Updates of the clinical evidences • Arrigo G. Cicero


LIPOPROTEINS AND ATHEROSCLEROSIS
What does low HDL‐C mean? • Laura Calabresi
ApoB a common denominator? • Brian Ference
TG lowering benefit: Clinical evidence • Alberto Zambon


DYSLIPIDEMIA MANAGEMENT: THE NEW 2019 EAS/ESC GUIDELINES
The EAS/ESC 2019 Dyslipidemia Guidelines • Alberico L. Catapano
Take home messages from EAS/ESC 2019 Dyslipidemia Guidelines • Lale Tokgözoğlu


CURRENT AND FUTURE THERAPEUTIC APPROACHES
Statins • Lale Tokgözoğlu
Ezetimibe and combination therapy • Luis Masana
PCSK9 inhibitors • Michel Farnier
Novel therapeutic approaches • Alberico L. Catapano

November 10, 2019

PRESENTATION AND DISCUSSION OF CLINICAL CASES
Low Risk (<1% and LDL >140 mg/dL) • Matteo Pirro, Maciej Banach
High risk patient, with FH, in primary prevention • Lale Tokgözoğlu, Michel Farnier
Initial state of Diabetes, medium‐high risk, high TG • Lluis Masana
High risk patient, with CKD, in primary prevention • Arrigo G. Cicero
High risk patient, with CKD, in primary prevention • Laura Calabresi
High risk patient, patient, Acute Coronary Syndrome • Carlos Escobar